Compare TLX & PBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLX | PBH |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | N/A | 2005 |
| Metric | TLX | PBH |
|---|---|---|
| Price | $7.76 | $65.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.00 | ★ $86.40 |
| AVG Volume (30 Days) | 190.3K | ★ 363.2K |
| Earning Date | 01-19-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.04 | ★ 4.04 |
| Revenue | $664,225,558.00 | ★ $1,110,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.50 |
| P/E Ratio | $239.61 | ★ $16.11 |
| Revenue Growth | ★ 55.35 | N/A |
| 52 Week Low | $7.31 | $57.25 |
| 52 Week High | $30.36 | $90.04 |
| Indicator | TLX | PBH |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 63.79 |
| Support Level | $7.42 | $64.34 |
| Resistance Level | $7.71 | $66.25 |
| Average True Range (ATR) | 0.15 | 1.63 |
| MACD | 0.07 | 0.22 |
| Stochastic Oscillator | 70.31 | 81.89 |
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.